BioCentury | Jun 5, 2019
Finance

EpimAb raises $74M series B round to accelerate bispecific immuno-oncology pipeline expansion

...participated, along with existing investors Oriza Seed Venture Capital, Decheng Capital, 3E Bioventures Capital and Trend Investment Group...
BioCentury | Apr 29, 2017
Finance

Building bispecifics

...Li of Oriza Seed Capital, which led the round. Decheng Capital, 3E Bioventures Capital and Trend Investment Group...
BioCentury | Apr 27, 2017
Financial News

EpimAb completes venture financing

...round led by Oriza Seed Capital. Also participating were Decheng Capital, 3E Bioventures Capital and Trend Investment Group...
BioCentury | Apr 25, 2017
Financial News

EpimAb raises $25M in series A

...round led by Oriza Seed Capital. Also participating were Decheng Capital, 3E Bioventures Capital and Trend Investment Group...
Items per page:
1 - 4 of 4
BioCentury | Jun 5, 2019
Finance

EpimAb raises $74M series B round to accelerate bispecific immuno-oncology pipeline expansion

...participated, along with existing investors Oriza Seed Venture Capital, Decheng Capital, 3E Bioventures Capital and Trend Investment Group...
BioCentury | Apr 29, 2017
Finance

Building bispecifics

...Li of Oriza Seed Capital, which led the round. Decheng Capital, 3E Bioventures Capital and Trend Investment Group...
BioCentury | Apr 27, 2017
Financial News

EpimAb completes venture financing

...round led by Oriza Seed Capital. Also participating were Decheng Capital, 3E Bioventures Capital and Trend Investment Group...
BioCentury | Apr 25, 2017
Financial News

EpimAb raises $25M in series A

...round led by Oriza Seed Capital. Also participating were Decheng Capital, 3E Bioventures Capital and Trend Investment Group...
Items per page:
1 - 4 of 4